Literature DB >> 33633408

A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity.

Sirui Zhou1,2, Guillaume Butler-Laporte1,2, Tomoko Nakanishi1,3,4,5, David R Morrison1, Jonathan Afilalo1,2,6, Marc Afilalo1,7, Laetitia Laurent1, Maik Pietzner8, Nicola Kerrison8, Kaiqiong Zhao1,2, Elsa Brunet-Ratnasingham9,10, Danielle Henry1, Nofar Kimchi1, Zaman Afrasiabi1, Nardin Rezk1, Meriem Bouab1, Louis Petitjean1, Charlotte Guzman1, Xiaoqing Xue1, Chris Tselios1, Branka Vulesevic1, Olumide Adeleye1, Tala Abdullah1, Noor Almamlouk1, Yiheng Chen1,3, Michaël Chassé9, Madeleine Durand9, Clare Paterson11, Johan Normark12, Robert Frithiof13, Miklós Lipcsey13,14, Michael Hultström13,15, Celia M T Greenwood1,2,16, Hugo Zeberg17, Claudia Langenberg8,18, Elin Thysell19, Michael Pollak1,20, Vincent Mooser3, Vincenzo Forgetta1, Daniel E Kaufmann9,21, J Brent Richards22,23,24,25.   

Abstract

To identify circulating proteins influencing Coronavirus Disease 2019 (COVID-19) susceptibility and severity, we undertook a two-sample Mendelian randomization (MR) study, rapidly scanning hundreds of circulating proteins while reducing bias due to reverse causation and confounding. In up to 14,134 cases and 1.2 million controls, we found that an s.d. increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (odds ratio (OR) = 0.54, P = 7 × 10-8), hospitalization (OR = 0.61, P = 8 × 10-8) and susceptibility (OR = 0.78, P = 8 × 10-6). Measuring OAS1 levels in 504 individuals, we found that higher plasma OAS1 levels in a non-infectious state were associated with reduced COVID-19 susceptibility and severity. Further analyses suggested that a Neanderthal isoform of OAS1 in individuals of European ancestry affords this protection. Thus, evidence from MR and a case-control study support a protective role for OAS1 in COVID-19 adverse outcomes. Available pharmacological agents that increase OAS1 levels could be prioritized for drug development.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33633408     DOI: 10.1038/s41591-021-01281-1

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  50 in total

1.  Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection.

Authors:  Werner E G Müller; Xiaohong Wang; Meik Neufurth; Heinz C Schröder
Journal:  Prog Mol Subcell Biol       Date:  2022

Review 2.  Effects of selected inherited factors on susceptibility to SARS-CoV-2 infection and COVID-19 progression.

Authors:  J A Hubacek
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

Review 3.  RNA regulatory mechanisms that control antiviral innate immunity.

Authors:  Nandan S Gokhale; Julian R Smith; Rachel D Van Gelder; Ram Savan
Journal:  Immunol Rev       Date:  2021-08-17       Impact factor: 12.988

4.  Specific Recognition of the 5'-Untranslated Region of West Nile Virus Genome by Human Innate Immune System.

Authors:  Emmanuelle Bignon; Marco Marazzi; Tom Miclot; Giampaolo Barone; Antonio Monari
Journal:  Viruses       Date:  2022-06-13       Impact factor: 5.818

5.  The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses.

Authors:  Yunus Kuijpers; Xiaojing Chu; Martin Jaeger; Simone J C F M Moorlag; Valerie A C M Koeken; Bowen Zhang; Aline de Nooijer; Inge Grondman; Manoj Kumar Gupta; Nico Janssen; Vera P Mourits; L Charlotte J de Bree; Quirijn de Mast; Frank L van de Veerdonk; Leo A B Joosten; Yang Li; Mihai G Netea; Cheng-Jian Xu
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

Review 6.  The human genetic epidemiology of COVID-19.

Authors:  Mari E K Niemi; Mark J Daly; Andrea Ganna
Journal:  Nat Rev Genet       Date:  2022-05-02       Impact factor: 59.581

7.  Proteomic profiling identifies novel proteins for genetic risk of severe COVID-19: the Atherosclerosis Risk in Communities Study.

Authors:  Brian T Steffen; James S Pankow; Pamela L Lutsey; Ryan T Demmer; Jeffrey R Misialek; Weihua Guan; Logan T Cowan; Josef Coresh; Faye L Norby; Weihong Tang
Journal:  Hum Mol Genet       Date:  2022-07-21       Impact factor: 5.121

8.  Integrative genomics analysis reveals a 21q22.11 locus contributing risk to COVID-19.

Authors:  Yunlong Ma; Yukuan Huang; Sen Zhao; Yinghao Yao; Yaru Zhang; Jia Qu; Nan Wu; Jianzhong Su
Journal:  Hum Mol Genet       Date:  2021-06-17       Impact factor: 6.150

9.  Local adaptation and archaic introgression shape global diversity at human structural variant loci.

Authors:  Stephanie M Yan; Rachel M Sherman; Dylan J Taylor; Divya R Nair; Andrew N Bortvin; Michael C Schatz; Rajiv C McCoy
Journal:  Elife       Date:  2021-09-16       Impact factor: 8.140

10.  Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor.

Authors:  Oded Danziger; Roosheel S Patel; Emma J DeGrace; Mikaela R Rosen; Brad R Rosenberg
Journal:  PLoS Pathog       Date:  2022-04-14       Impact factor: 7.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.